HealthEquity’s DCF Model Points to 48% Upside Despite Rich Market Multiples — BigGo Finance

A fresh valuation analysis of HealthEquity Inc. (HQY) suggests the health savings account administrator may be trading at a steep discount to its intrinsic worth, even as conventional market multiples paint a less flattering picture. The question for investors is whether the company’s ability to generate consistent free cash flow justifies a more generous valuation than the market currently assigns.

HealthEquity has delivered a 41.2% total return over the past five years, rewarding long-term holders despite recent share price softness. The company’s fiscal second-quarter results, reported Thursday, showed net income of $65.6 million, or 78 cents per share. Adjusted earnings came in at $1.24 per share, beating the $1.19 consensus estimate from analysts surveyed by Zacks Investment Research. Revenue of $350.7 million also edged past the $350.2 million Street forecast.

For the full fiscal year, management guided to earnings of $4.66 to $4.73 per share on revenue of $1.41 billion to $1.42 billion.

The valuation debate centers on a Discounted Cash Flow model that projects HealthEquity’s free cash flow generation into the future. The company produced approximately $266 million in trailing twelve-month free cash flow, and the model assumes that figure continues to expand. Using a two-stage Free Cash Flow to Equity framework, the analysis arrives at an estimated intrinsic value of roughly $179 per share. That implies the stock is priced at a 47.7% discount to the DCF estimate.

However, the broader valuation picture is less decisive. The stock scores 4 out of 6 on value measures, reflecting a mixed signal: cash flow-based metrics point to undervaluation, while market-based multiples appear stretched. The tension between these two approaches defines the current investment debate.

HealthEquity operates a platform for managing health savings accounts, a business model that converts account growth and fee income into recurring cash flows. Any slowdown in account additions or erosion in fee economics would directly pressure the cash flow projections underpinning the DCF valuation. That sensitivity is the primary risk to the bullish case.

For investors, the central question is whether the recent pullback in HealthEquity shares, combined with the DCF-implied discount, offers adequate compensation for the richer multiples currently embedded in the stock price. The answer depends heavily on one’s confidence in the durability of the company’s free cash flow profile.

Note: Earnings and revenue figures reflect fiscal second-quarter results reported August 27, 2026. Valuation metrics are based on the DCF model described in the analysis.

The divergence between the DCF estimate and market-based multiples highlights a broader tension in how investors are pricing HealthEquity. A stock can appear cheap on one framework and expensive on another when the market is applying a premium for growth expectations that may or may not materialize. In HealthEquity’s case, the market appears to be demanding proof that the cash flow engine can keep compounding before closing the gap.

For those who believe the company’s platform economics remain intact, the 48% discount represents a meaningful margin of safety. For skeptics, the stretched multiples suggest the market has already priced in a significant amount of future growth, leaving little room for error.